Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott scrutinizes Sandoz’ Biaxin generics

Executive Summary

Abbott says it will evaluate Sandoz' clarithromycin ANDAs and take "appropriate measures to protect its intellectual property" covering the Biaxin franchise. FDA approved Sandoz' ANDAs for clarithromycin immediate- and extended-release on Aug. 25; the products have not yet launched. Abbott is in patent litigation with several companies to keep Biaxin XL generics off the market, but Sandoz is not part of that litigation. Immediate-release Biaxin generics launched in May upon expiration of Abbott's compound patent...

Topics

UsernamePublicRestriction

Register

PS046269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel